Tisagenlecleucel for Treatment of Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia (R/R B-All): A Systematic Review of Cost-Effectiveness Analysis

Abstract

Tisagenlecleucel is a new immunological therapy in refractory or relapsed B-cell lymphoblastic leukemia with high expense. Objective: Assess the quality as well as analyze characteristics and results of cost-effectiveness analysis (CEA) of tisagenlecleucel immunological therapy in children with R/R B-ALL. Method: Analyze a systematic review of articles published from 2017 to 2023 in Pubmed, ScienceDirect, Google Scholar, and Cochrane databases. Result: 10 selected studies were carried out in 8 nations with different cost units and discount rates. Compared therapies were standard therapy of each country included Blinatumomab, Clo-C, Clo-M, FLA-IDA, and FLAG-IDA. Of 10 studies, 70% was considered cost-effectiveness, 20% non-conclusion, and only 10% not cost-effectiveness. Conclusion: Tisagenlecleucel’s cost is the highest among compared therapies but it can be cost-effective in a nation with a WTP threshold of $100.000-$150.000.